Insider Trading Alert - RMD, TWTC And AMP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 20, 2014, 164 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $87.78 to $643,360,199,551.68.

Highlighted Stocks Traded by Insiders:

ResMed (RMD) - FREE Research Report

Sandercock Brett who is Chief Financial Officer at ResMed sold 8,100 shares at $46.00 on Feb. 20, 2014. Following this transaction, the Chief Financial Officer owned 76,115 shares meaning that the stake was reduced by 9.62% with the 8,100-share transaction.

The shares most recently traded at $46.35, up $0.35, or 0.76% since the insider transaction. Historical insider transactions for ResMed go as follows:

  • 4-Week # shares sold: 11,187
  • 12-Week # shares sold: 61,687
  • 24-Week # shares sold: 112,750

The average volume for ResMed has been 1.2 million shares per day over the past 30 days. ResMed has a market cap of $6.5 billion and is part of the health care sector and health services industry. Shares are down 2% year-to-date as of the close of trading on Thursday.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The stock currently has a dividend yield of 2.17%. The company has a P/E ratio of 20.7. Currently there are 5 analysts that rate ResMed a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RMD - FREE

TheStreet Quant Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full ResMed Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates